FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a fused ring compound containing furan or a pharmaceutically acceptable salt thereof, a method for preparing same, a pharmaceutical composition comprising same, and a use thereof. The fused ring compound containing furan or a pharmaceutically acceptable salt thereof in...

Full description

Saved in:
Bibliographic Details
Main Authors SEO, HYOUNG SIG, LEE, GYU JIN, LIM, HEE JONG, LEE, HYUN JOO, KIM, DONG HOON, LEE, GE HYEONG, PARK, JUN CHUL, PARK, KAAPJOO, KIM, TAE KYUN, AHN, KYOUNG KYU, KIM, TAE-HOON, NAM, SU YOUN, HYUN, KWAN HOON, GAL, JI YEONG
Format Patent
LanguageEnglish
French
Korean
Published 30.01.2014
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a fused ring compound containing furan or a pharmaceutically acceptable salt thereof, a method for preparing same, a pharmaceutical composition comprising same, and a use thereof. The fused ring compound containing furan or a pharmaceutically acceptable salt thereof inhibits the activity of phosphatidylinositol 3-kinase (PI3K) and can therefore be used in a pharmaceutical composition for treating and preventing respiratory diseases, inflammatory diseases, proliferative diseases, cardiovascular diseases, or central nervous system diseases which occur due to the over-activation of PI3K. La présente invention concerne un composé à cycles fusionnés contenant du furane ou un sel pharmaceutiquement acceptable de celui-ci, un procédé de préparation associé, une composition pharmaceutique le comprenant, et une utilisation associée. Le composé à cycles fusionnés contenant du furane ou un sel pharmaceutiquement acceptable de celui-ci inhibe l'activité de la phosphatidylinositol 3-kinase (PI3K) et peut être utilisé dans une composition pharmaceutique de traitement ou de prévention de maladies respiratoires, de maladies inflammatoires, de maladies prolifératives, de maladies cardio-vasculaires, ou de maladies du système nerveux central qui se produisent en raison de la suractivation de PI3K.
Bibliography:Application Number: WO2013KR06581